Protocol Ledger

NCT07686263 · Phase III · RECRUITING

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Interventional Phase III clinical trial protocol NCT07686263 sponsored by Bristol Myers Squibb in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-20 Enrollment: 472 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07686263
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)472 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07686263
Protocol FieldVerified Registry Value
NCT IdentifierNCT07686263
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment472 participants (ESTIMATED)
Registered Start Date2026-08-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07686263
Hospital Research SiteLocationSite Profile
NRC Research InstituteOrange, CAOpen Hospital Dossier ->
Atlanta Center for Medical ResearchAtlanta, GAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI